P53-targeted cancer pharmacotherapy: Move towards small molecule compounds

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 5, 2011, Pages 603-610

  Kim, Soo Hyun ^a   Dass, Crispin R ^b  

^a The Catholic University of Korea   (South Korea)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

apoptosis; cancer; chemotherapy; drug; p53; tumour

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BENZODIAZEPINEDIONE; CDB 3; CONTUSUGENE LADENOVEC; DNA; ELLIPTICINE; GENDICINE; HLI 98; LEPTOMYCIN B; MESSENGER RNA; MI 219; MI 319; NSC 652287; NUTLIN DERIVATIVE; ONCORINE; ONYX 015; PHIKAN 083; PRIMA 1; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETRA; RITA; SIMP; TENOVIN 1; TENOVIN 6; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; DNA DAMAGE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; MULTIGENE FAMILY; NONHUMAN; OSTEOSARCOMA; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; GENES, P53; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954818122     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01248.x     Document Type: Article

References (109)

1. Koshland DE Jr,. Molecule of the year. Science 1993; 262: 1953. (Pubitemid 24041867)
2. Nezhadi SH, et al,. Gelatin-based delivery systems for cancer gene therapy. J Drug Target 2009; 17: 731-738.
3. Ma G, et al,. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther 2009; 2: 115-122.
4. Yang ZX, et al,. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136: 625-630.
5. Lu W, et al,. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004; 10: 3634-3638. (Pubitemid 39619282)
6. Donehower LA, et al,. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
7. Frebourg T, et al,. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995; 56: 608-615.
8. Varley JM, et al,. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57: 3245-3252. (Pubitemid 27351742)
9. Malkin D, et al,. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238. (Pubitemid 120031831)
10. Vogelstein B, Kinzler KW,. p53 function and dysfunction. Cell 1992; 70: 523-526.
11. Bálint EE, Vousden KH,. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001; 85: 1813-1823. (Pubitemid 34775315)
12. Teodoro JG, et al,. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007; 85: 1175-1186. (Pubitemid 47622219)
13. Maiuri MC, et al,. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22: 181-185.
14. Brown CJ, et al,. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-873.
15. Kaghad M, et al,. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819. (Pubitemid 27357971)
16. Yang A, et al,. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316. (Pubitemid 128379271)
17. Machado-Silva A, et al,. p53 family members in cancer diagnosis and treatment. Semin Cancer Biol 2010; 20: 57-62.
18. Murray-Zmijewski F, et al,. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
19. Rosenbluth JM, Pietenpol JA,. The jury is in: p73 is a tumor suppressor after all. Genes Dev 2008; 22: 2591-2595.
20. Finlan LE, Hupp TR,. p63: the phantom of the tumor suppressor. Cell Cycle 2007; 6: 1062-1071. (Pubitemid 46708579)
21. Vilgelm A, et al,. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 2008; 11: 152-163.
22. Marine JC, et al,. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
23. Kim E, Deppert W,. The complex interactions of p53 with target DNA: we learn as we go. Biochem Cell Biol 2003; 81: 141-150. (Pubitemid 37076236)
24. Vousden KH, Prives C,. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
25. Green DR, Kroemer G,. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
26. Haupt Y, et al,. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995; 9: 2170-2183.
27. Caelles C, et al,. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-223. (Pubitemid 24236778)
28. Murphy ME, et al,. p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 2004; 3: 836-839. (Pubitemid 40179452)
29. El-Deiry WS, et al,. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825. (Pubitemid 23346378)
30. Rouault JP, et al,. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996; 14: 482-486.
31. Hollander MC, et al,. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem 1993; 268: 24385-24393. (Pubitemid 23335431)
32. Hermeking H, et al,. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11. (Pubitemid 127376388)
33. Kortlever RM, Bernards R,. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006; 5: 2697-2703. (Pubitemid 44901726)
34. Cazzalini O, et al,. p21CDKN1A participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1. DNA Repair (Amst) 2010; 9: 627-635.
35. Yamaguchi T, et al,. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001; 61: 8256-8262. (Pubitemid 33091620)
36. Hwang BJ, et al,. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 1999; 96: 424-428. (Pubitemid 29061224)
37. Miyashita T, Reed JC,. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
38. Buckbinder L, et al,. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
39. Wu GS, et al,. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
40. Nakano K, Vousden KH,. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694. (Pubitemid 32706359)
41. Oda E, et al,. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058. (Pubitemid 30324238)
42. Owen-Schaub LB, et al,. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
43. Green DR, Chipuk JE,. p53 and metabolism: inside the TIGAR. Cell 2006; 126: 30-32.
44. Corcoran CA, et al,. The regulation of energy generating metabolic pathways by p53. Cancer Biol Ther 2006; 5: 1610-1613.
45. Dameron KM, et al,. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584. (Pubitemid 24308973)
46. Teodoro JG, et al,. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006; 313: 968-971. (Pubitemid 44267388)
47. Crighton D, et al,. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-134. (Pubitemid 44040988)
48. Mathew R, et al,. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967. (Pubitemid 350165856)
49. Molchadsky A, et al,. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008; 3: e3707.
50. Liu H, Li B,. p53 control of bone remodeling. J Cell Biochem 2010; 111: 529-534.
51. D'Erchia AM, et al,. The fatty acid synthase gene is a conserved p53 family target from worm to human. Cell Cycle 2006; 5: 750-758.
52. Kuhajda FP,. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-208. (Pubitemid 30114274)
53. Lu S, Archer MC,. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 2005; 26: 153-157. (Pubitemid 40207710)
54. Waxman DJ, Schwartz PS,. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003; 63: 8563-8572. (Pubitemid 38064026)
55. DeGregori J, Johnson DG,. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006; 6: 739-748. (Pubitemid 44725567)
56. Iaquinta PJ, Lees JA,. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19: 649-657. (Pubitemid 350216426)
57. Lowe SW, et al,. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967. (Pubitemid 23289454)
58. Urist M, et al,. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004; 18: 3041-3054. (Pubitemid 39658173)
59. Chandar N, et al,. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 1992; 65: 208-214.
60. Miller CW, et al,. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996; 122: 559-565. (Pubitemid 26284557)
61. McIntyre JF, et al,. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12: 925-930. (Pubitemid 24145318)
62. Hauben EI, et al,. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003; 11: 611-618. (Pubitemid 37038776)
63. Oren M,. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-442. (Pubitemid 36626355)
64. Lonardo F, et al,. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 1997; 79: 1541-1547. (Pubitemid 27154785)
65. DeCruz EE, et al,. The basis for somatic gene therapy of cancer. J Exp Ther Oncol 1996; 1: 73-83.
66. Ventura A, et al,. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665. (Pubitemid 46232887)
67. Xue W, et al,. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660. (Pubitemid 46232886)
68. Martins CP, et al,. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-1334. (Pubitemid 44960417)
69. Wolf JK, et al,. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004; 94: 442-448. (Pubitemid 39024551)
70. Ries S, Korn WM,. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11. (Pubitemid 34146332)
71. Oshima Y, et al,. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol Ther 2007; 6: 1058-1066. (Pubitemid 351574957)
72. Das S, et al,. p73 beta-expressing recombinant adenovirus: a potential anticancer agent. Cancer Gene Ther 2005; 12: 417-426. (Pubitemid 40411201)
73. Vassilev LT, et al,. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848. (Pubitemid 38174664)
74. Shangary S, Wang S,. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-241.
75. Mohammad RM, et al,. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009; 8: 115.
76. Koblish HK, et al,. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006; 5: 160-169.
77. Issaeva N, et al,. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328. (Pubitemid 40022713)
78. Yang Y, et al,. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559. (Pubitemid 40799248)
79. Kudo N, et al,. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-9117. (Pubitemid 29374716)
80. Lain S, et al,. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-463. (Pubitemid 351609441)
81. Foster BA, et al,. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-2510.
82. Bykov VJ, et al,. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288. (Pubitemid 34250107)
83. Peng Y, et al,. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003; 22: 4478-4487. (Pubitemid 36920691)
84. Friedler A, et al,. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002; 99: 937-942. (Pubitemid 34106614)
85. Boeckler FM, et al,. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105: 10360-10365.
86. Kravchenko JE, et al,. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-6307. (Pubitemid 351758341)
87. Di Agostino S, et al,. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 2008; 7: 3440-3447.
88. Vazquez A, et al,. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-987.
89. Wilson JM,. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009; 96: 151-157.
90. Somia N, Verma IM,. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-99.
91. Hartman ZC, et al,. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132: 1-14. (Pubitemid 351232078)
92. Petitjean A, et al,. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629. (Pubitemid 46744292)
93. Selivanova G, Wiman KG,. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26: 2243-2254. (Pubitemid 46536645)
94. Woods YL, Lane DP,. Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol J 2003; 4: 233-247. (Pubitemid 36987219)
95. Selivanova G, et al,. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3: 632-638. (Pubitemid 27264972)
96. Kim AL, et al,. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999; 274: 34924-34931. (Pubitemid 129509540)
97. Demma MJ, et al,. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004; 279: 45887-45896. (Pubitemid 39491581)
98. Wischhusen J, et al,. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003; 22: 8233-8245. (Pubitemid 37485516)
99. Momand J, et al,. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
100. Linares LK, et al,. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003; 100: 12009-12014. (Pubitemid 37271506)
101. Enge M, et al,. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171-183.
102. Duan W, et al,. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606. (Pubitemid 35246863)
103. Leker RR, et al,. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol 2004; 187: 478-486. (Pubitemid 38610294)
104. de la Monte SM, et al,. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997; 152: 73-83. (Pubitemid 27469712)
105. Bourdon JC,. p53 Family isoforms. Curr Pharm Biotechnol 2007; 8: 332-336.
106. Aoubala M, et al,. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ 2011; 18: 248-258.
107. Liu X, et al,. Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004; 286: H933-H939. (Pubitemid 38248606)
108. Zhang M, et al,. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003; 120: 191-205. (Pubitemid 36782642)
109. Strom E, et al,. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2: 474-479. (Pubitemid 44266309)